The Members of the BioNJ Board of Trustees are thoughtful, engaged, and committed to the work of BioNJ and we are deeply indebted for their passion for Patients and for inspiring our work each day.
Chairman: Francois Nader, M.D.
NPS Pharmaceuticals, Inc., President and Chief Executive Officer
Francois Nader, M.D., has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharmaceuticals since 2008. During his tenure, Dr. Nader transformed NPS into a leading global biotechnology company focused on pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide. NPS’ lead product, Gattex® (US)/Revestive® (EU) for adult Short Bowel Syndrome, was approved in the US and Europe in 2012. NPS has also developed Natpara® for hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013. Recognizing his role in transforming NPS into a successful life sciences company, Dr. Nader was the recipient of the 2013 Ernst & Young National Entrepreneur Of The Year® Award in the Life Sciences category. This award is regarded as the world’s most prestigious business award for entrepreneurs.
Dr. Nader was named by BioNJ as the 2013 Dr. Sol J. Barer Honoree for Vision, Innovation and Leadership, the top award granted by BioNJ.
Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS in 2006 as Chief Medical and Commercial Officer, and was promoted to Chief Operating Officer in 2007. Prior to joining NPS Dr. Nader was a Venture Partner at Care Capital.
At Aventis and its predecessor companies, Dr. Nader served on the North America Leadership Team and held a number of executive positions including Senior Vice-President, Integrated Healthcare Markets; Senior Vice-President, North America Medical and Regulatory Affairs; and Vice-President US Medical Affairs and Global Health Economics and Outcome Research. Previously, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc in France.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee. Dr. Nader is chairman of the Board of Trustees for BioNJ. He is also a member of the boards of the Biotechnology Industry Organization (BIO) and the New Jersey Chamber of Commerce.
Immediate Past Chair: Sol J. Barer, Ph.D.
Celgene Corporation, Former Chairman
Dr. Barer is the Former Chairman and CEO of Celgene. He was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and Executive Chairman subsequently until January 1, 2011 when he transitioned to his current position. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990.
Dr Barer joined the Celanese Research Company in 1974 and formed the Biotechnology group that was subsequently spun out to form Celgene.
Dr. Barer holds numerous professional awards including the “Lifetime Achievement Award” (International Myeloma Foundation), “Outstanding Individual Award” (The Biotech Meeting 2010), “Dream & Promise Award” (Children’s Brain Tumor Foundation) “Odyssey Award” (Center for Medicine in the Public Interest), the “Corporate Vision Award” (Gilda’s Club), the “Sparkle of Hope Award” (Community Hope), “Master Entrepreneur Award” (Ernst & Young), “The Hall of Distinguished Alumni Award” (Rutgers University Alumni Federation), “Dr. Sol J. Barer Award for Vision, Innovation and Leadership” (BioNJ), “Science and Technology Industry Medal” (R&D Council of NJ), “Rutgers University Graduate School Annual Distinguished Alumnus Award”, “Winthrop-Sears Medal” (The Chemists Club and the Chemical Heritage Foundation), and “Albert Einstein Award in Life Sciences” (Global Capital Associates and Jerusalem Fund, Israel), “DART/NYU Biotechnology Achievement Award in Applied Biotechnology” (Biotechnology Study Center of the New York University School of Medicine).
Dr. Barer serves as Chairman of the Board of Cerecor, Chairman of the Board of ContraFect, Chairman of the Board of Edge Therapeutics, Chairman of the Board of InspireMD, Chairman of the Board of RestorGenex and Chairman of the Board of Medgenics and is on the Board of Directors of Aegerion Pharmaceuticals and Amicus Therapeutics. He serves as an advisor to biotechnology/medical companies. He served as Chair of the Board of BioNJ from 2010-2012, was Chairman of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee, served as a Commissioner of the NJ Commission on Science and Technology and was a member of the Board of Trustees of Rutgers – The State University of New Jersey.
Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University and B.S. from Brooklyn College.
President and CEO: Debbie Hart, MS, CAE, APR
BioNJ, President and CEO
Debbie Hart, founding President and CEO of BioNJ, is dedicated to the mission and work of BioNJ. She worked alongside New Jersey’s biotechnology industry leaders to establish BioNJ in 1994 and has been dedicated to the organization since then. Debbie has been active on the boards and committees of numerous government and academic institutions.
She served on the transition teams of two former New Jersey governors and was recently appointed by Gov. Chris Christie and Lt. Governor Kim Guadagno to the Council on Innovation. She is a member of the New Jersey Economic Development Authority’s (EDA) Technology Advisory Board and a former member and Chair of EDA’s Commercialization Center for Innovative Technologies (CCIT). Debbie was appointed by two Governors to the New Jersey Israel Commission for her work in economic development.
Past government support activities include the Prosperity New Jersey Pharmaceutical and Biotechnology Cluster Study commissioned by a former Governor and conducted by Professor Michael Porter of the Harvard Business School, the Jobs Growth and Economic Development Commission established by a former Governor and chaired by Dr. Roy Vagelos as well as the Task Force on Higher Education Quality and Competitiveness of the State. She also served on the Business Task Force established by the New Jersey State Legislature in 2011.
A strong advocate for advancing education, she is a board member of the Rutgers University Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management at Rutgers University Business School, the Advisory Board of the College of Science and Mathematics at Montclair University and a former board member of the Rothman Institute of Entrepreneurship at Fairleigh Dickinson University’s Silberman College of Business and the Science Advisory Board at Rider University as well as the advisory boards for the New Jersey Institute of Technology’s (NJIT) Biomedical Engineering Program, Monmouth University’s School of Science, Technology and Engineering and as a Director of the Liberty Science Center’s Women’s Leadership Council.
She served on the advisory board that guided the establishment of the nationally recognized Monmouth County Biotechnology High School as well a member of the New Jersey Healthcare Businesswomen’s Association (HBA) Advisory Board. In 2005, Debbie delivered the Commencement Address at Raritan Valley Community College’s graduation ceremonies.
As an advocate for the industry, Debbie has testified before State and federal legislative committees. She is also a frequent speaker at industry events, including serving as the Keynote speaker at the 2011 Russian Pharmaceutical Forum in St. Petersburg and the 2011 Knowledge for Growth Conference in Ghent, Belgium as well as the Women’s Clinical Leadership Forum at the Partnerships in Clinical Trials conference in Orlando, Florida in 2012 and the Shanghai Bio Conference in Shanghai in 2008.
Debbie has been honored by the Women’s Fund of New Jersey as a Woman Advancing Science, and Debbie and BioNJ have been recognized by NJIT with a New Jersey Inventors Hall of Fame Award.
She was named twice to the NJBIZ Power 100, a listing of the 100 most influential people in New Jersey business and is a NJBIZ New Jersey’s Best 50 Women in Business honoree. In March 2014 in commemoration of Women’s History Month, she was honored by the New Jersey General Assembly as a Woman Advancing Science. In May 2014, Debbie was named as one of 50 people to PolitickerNJ’s Health Care Power List of 2014.
Debbie holds an M.S. from the S. I. Newhouse School at Syracuse University where she graduated cum laude and a B.A. from Trenton State College, now The College of New Jersey, where she graduated magna cum laude.
Vice Chairman: Christopher J. Schaber, Ph.D.
Soligenix, Inc., President and Chief Executive Officer
Christopher J. Schaber, Ph.D. has over 25 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been Soligenix’s President and Chief Executive Officer and a director since August 2006.
He also serves on the board of directors for the Alliance for BioSecurity and as vice chair of BioNJ. He is a member of the corporate councils for both the National Organization for Rare Diseases (NORD) and the American Society for Blood and Marrow Transplantation (ASBMT).
Prior to joining the company, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, he was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, he was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories.
Dr. Schaber received his BA from Western Maryland College, his MS in Pharmaceutics from Temple University School of Pharmacy and his PhD in Pharmaceutical Sciences from the Union Graduate School. During his career, Dr. Schaber has played a significant role in raising in excess of $200 million through both public offerings and private placements.
Secretary: Donna Tempel, Ph.D., M.B.A.
Drais Pharmaceuticals Inc., President and Chief Executive Officer
Dr. Tempel is President, Chief Executive Officer and co-founder of Drais Pharmaceuticals Inc. Drais is a venture-capital supported clinical drug development company, based in Bridgewater, New Jersey. The company specializes in early phase clinical development and seeks to establish close partnerships with larger pharmaceutical companies in order to build its pipeline and accelerate promising candidates to proof of concept.
Prior to founding Drais, Dr. Tempel was co-founder and Chief Operating Officer of AkaRx, Inc., also a venture-backed development company. AkaRx was spun out of the merger of Yamanouchi and Fujisawa in 2005 with a focus in hematology/oncology. AkaRx was acquired by Eisai Inc. in January of 2010. Prior to the founding of AkaRx Inc., Dr. Tempel was Vice President of Project Management at Yamanouchi, responsible for oversight of all clinical development programs for the company in the US and EU including the now-marketed products, Vesicare™ and Vaprisol™. Prior to joining Yamanouchi in 1998, Dr. Tempel held various positions in Research and Development at Bristol-Myers Squibb and Johnson & Johnson, Inc.
Dr. Tempel currently serves as the Secretary of BioNJ. She received her B.S. in Psychology and Mathematics from Hunter College/CUNY, a Ph.D. in Neuroscience from CUNY/Mount Sinai School of Medicine and an MBA in Finance from Farleigh Dickinson University.
Treasurer: Elizabeth Posillico, Ph.D.
Elusys Therapeutics, Inc., President and Chief Executive Officer
Elizabeth has 25 years of experience in the biopharmaceutical industry and has held senior positions in general management, business development, marketing and operations. She joined Elusys in 2002 as Vice President of Business Development and since then was promoted to Sr. Vice President of Operations and then President and CEO in January, 2005.
Prior to joining Elusys, she was Vice President of Business Development and Marketing at Physiome Sciences, Sr. Vice President of Business Development at Apoptogen, Inc., a Canadian biotech company developing novel therapies for the treatment of apoptosis-related diseases. She also served on the management committee of the Canadian Medical Discovery Fund, an early-stage venture capital fund. Elizabeth spent eight years at Genzyme Corporation in several positions including Director of Sales and Marketing for ImmunoBiological Products and ultimately as General Manager and Sr. Vice President in the Diagnostics Division.
She currently serves as Co-Chair of the Alliance for Biosecurity and as Treasurer on the Board of Directors of BioNJ. Elizabeth received a BA degree from the State University of New York at Potsdam and a PhD from Duke University.
Agile Therapeutics, President and Chief Executive Officer
Al Altomari is the President and Chief Executive Officer of Agile Therapeutics and a member of the Company’s Board of Directors. Prior to being named President and CEO, Mr. Altomari served as Agile’s Executive Chairman in which capacity he closed a $45 million venture round in May 2010. Mr. Altomari has more than 28 years of experience in the pharmaceutical industry, with more than 20 years focused on the development and marketing of specialty pharmaceutical products. Currently Mr. Altomari is leading Agile through the final stages of development and commercialization of contraceptive products using the Company’s proprietary transdermal technology.
Prior to joining Agile Therapeutics, Mr. Altomari served as Chief Executive Officer of Barrier Therapeutics and as a member of the Company’s Board of Directors. In 2008, Mr. Altomari completed the successful sale of the Company (NASDAQ: BTRX) to GSK/Stiefel Laboratories for a 73% premium. His initial role with the Company had been as Chief Commercial Officer, beginning in August 2003, and he was promoted to Chief Operating Officer in February 2006. During his tenure at Barrier, Mr. Altomari set up Barrier’s commercial infrastructure, all sales and marketing activities for Barrier’s product portfolio and oversaw management of all worldwide business development initiatives.
Prior to joining Barrier, Mr. Altomari functioned in numerous executive roles in general management, commercial operations, business development, product launch preparation and finance within Johnson & Johnson from 1982 to 2003. He completed his tenure with Johnson & Johnson as General Manager of Ortho Neutrogena, where he successfully led the integration of Ortho Dermatological and Neutrogena Professional. Mr. Altomari also served as Vice President/Franchise Head of Ortho-McNeil Pharmaceutical’s Women’s Health Care Franchise where he introduced several life cycle and new product development initiatives, including launching Ortho Evra®, a contraceptive patch. Sales of the Women’s Health Care Franchise were well in excess of $1 billion.
Mr. Altomari currently serves as a member of the Board of Directors of DUSA Pharmaceuticals Inc. (NASDAQ: DUSA) and NB Therapeutics. In July 2007, Mr. Altomari was recognized by PharmaVOICE Magazine as one of the Top 100 Most Inspirational and Influential Leaders in the Life Sciences Industry. He received a Master’s in Business Administration from Rider University in Lawrenceville, New Jersey, and his Bachelor of Science degree from Drexel University in Philadelphia, Pennsylvania, with a dual major in finance and accounting. Mr. Altomari currently serves on the Le Bow College (Drexel’s Business School) advisory board.
Marc Bonnefoi, DVM, Ph.D.
Sanofi, Head of the North America R&D Hub and Global Head, Drug Disposition, Preclinical Safety and Animal Research
Marc Bonnefoi is Head of Sanofi’ s North America R&D Hub which includes the R&D activities of Genzyme, Merial, Pharma, and Sanofi-Pasteur in the region. He also heads the global Scientific Core Platform Drug Disposition, Preclinical Safety and Animal Research, which support all Sanofi therapeutic units and Divisions.
Marc has worked at Sanofi and predecessor companies for more than 20 years in positions of increasing level of responsibility. Prior to this he was Assistant-Professor of Pharmacology and Toxicology at the Veterinary School of Toulouse, France.
Marc earned a doctorate in veterinary medicine and a Ph.D. in pharmacology from the University of Toulouse in France.
John F. Crowley
Amicus Therapeutics, Inc., Chairman and Chief Executive Officer
John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the co-founder, president and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives.) In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.
John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope and Joy.
John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He serves on the executive committee of the National Board of Directors of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.
Pamela M. Demain, MBA, CLP
Merck & Co., Inc., Executive Director, Transactions Business Development and Licensing
Pamela Demain is Executive Director, Transactions, Business Development and Licensing, Merck & Co., Inc. She has been at Merck for over 30 years. For the past 19 years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations and research platform technologies.
Pam also heads up the relationship development area, which includes responsibility for Merck’s partnering outreach program, initiating new business development opportunities and building relationships with companies and universities worldwide. Since 2000, she has been instrumental in the strategic transformation of Merck from an inward-looking to an outward-facing company focused on partnerships with companies and universities worldwide.
Prior to her current position, Ms. Demain was in charge of the Business Information & Research Department in the Worldwide Human Health Marketing area of Merck, providing global strategic decision support for all of Merck’s new and in-line products.
Previous positions at Merck include 13 years in Corporate Planning, Marketing Communications and Product Management, where she was responsible for the worldwide launch of PRIMAXIN/TIENAM. She joined Merck in 1981 as part of the MBA management training program.
Pamela’s pharmaceutical career began in the natural products laboratory of Gruppo Lepetit, an Italian pharmaceutical company, which was then a subsidiary of the Dow Chemical Company. Ms. Demain is a graduate of the University of Massachusetts at Amherst, and holds a M.B.A. in International Business from The American University in Washington, D.C. and is a Certified Licensing Professional (CLP).
Pam has been on the Board of Trustees for the Licensing Executive Society (USA & Canada) since 2006 and is currently President-Elect. Her previous positions on the Board have been VP for Communications, Regional VP for the US, and Trustee for Partnering. Her most recent accomplishments include the Life Science Sector Strategic Initiative and establishing the LES Insights weekly e-newsletter. She has been a member of the LES Life Sciences Committee since 2003. In 2012, she was honored by LES with the Frank Barnes Mentoring Award. In September 2013, Pam joined the Board of BioNJ.
Celgene Corporation, Senior Vice President, Business Development
In a career spanning nearly 20 years, George has held senior positions in R&D and Business Development. In his most recent two positions, he has led business development functions at leading oncology companies. He has a strong record of closing significant in-licensing and M&A transactions.
George is currently Senior Vice President of Business Development for Celgene Corporation, where he is responsible for the full array of business development activities (identification & evaluation of opportunities, structuring & negotiating transactions, in-licensing, M&A, outlicensing, and alliance management). At Celgene, these activities are focused within the therapeutic areas of oncology and inflammation.
Prior to Celgene, George served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology. During his tenure at Novartis, George’s group closed a significant number of collaboration agreements which bolstered the development pipeline. Earlier in his career, George held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to in-license rotigotine and lacosamide (both now approved agents). In most of his positions, George has served on the R&D and/or Corporate Leadership Teams.
George received a BA in Biology from the University of Virginia, a PhD in Genetics from the University of Wisconsin-Madison. He has spoken frequently at industry conferences and leading business schools on a variety of topics related to the collaborations within the biopharmaceutical industry.
Christian Kopfli, Esq.
Chromocell Corporation, Chief Executive Officer
Christian co-founded Chromocell in 2002, serving initially as General Counsel before becoming Chief Executive Officer in 2005.
Prior to joining Chromocell, he was an Associate at Davis Polk & Wardwell, working in its New York City, Tokyo and Frankfurt offices.
At Davis Polk, Christian worked extensively in Mergers & Acquisitions, Capital Markets and Private Equity Transactions.
He received a doctoral degree in law (magna cum laude) from the University of Zurich in 2000 and earned his LL.M. from Columbia Law School in New York City in 1998. Christian is a Board Member of BioNJ and admitted to the Bar in New York and Switzerland.
William H. Lewis
Insmed Incorporated, President and Chief Executive Officer
Will joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will has more than 20 years of executive experience and a track record of success in the pharmaceutical and finance industries both in the US and internationally.
He is the Co-Founder, and former President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). During his tenure at Aegerion, Will played a pivotal role in re-orienting the company’s strategy to focus on orphan disease indications enabling Aegerion to go public in one of the best performing IPOs of 2010. Prior to Aegerion, Will spent more than 10 years working in the US and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. During his time in banking, he was involved in a broad range of domestic and international capital raises and advisory work valued at more than $20 billion.
Will serves as a member of the Board of Directors of Oberlin College, He serves as a member of the Visiting Committee of the Weatherhead School of Management of Case Western Reserve University. Will holds a BA Cum Laude from Oberlin College and an MBA/JD with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government.
Vicus Therapeutics, President and Chief Executive Officer
John Maki previously served as Managing Director of Technology Directors, Inc., as Managing Director of Audax Group and as Principal, Bain Capital, as well as consultant, Bain & Company.
Mr. Maki holds an AB degree from Harvard University. Mr. Maki has over 25 years of industry experience and has been founding investor and/or board member of eleven life science companies. In addition, four of Mr. Maki’s portfolio companies had successful IPOs and grew to a combined market capitalization exceeding $2.5 billion dollars. Mr. Maki currently serves on the boards of 3DMatrix, a wound healing device company and Vicus Therapeutics. Mr. Maki also serves on the Board of Trustees of BioNJ.
Anthony Marucci, MBA
Celldex Therapeutics, Inc., Founder, President, Chief Executive Officer and Director
Mr. Marucci is a Founder of Celldex and served as its Vice President, Chief Financial Officer, Treasurer and Secretary since inception and prior to his appointments to Executive Vice President in March 2008, President and Chief Executive Officer in October 2008, and the Board of Directors in December 2008. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci received his B.S. in Accounting from Kean University and his M.B.A. from Columbia University.
David Pearson, Ph.D., MBA
President, ThromboGenics, Inc. And Global Head of Corporate Development, ThromboGenics, Inc.
David Pearson, Ph.D., MBA, is an accomplished biopharmaceutical industry executive with more than 25 years of senior management experience in technical, operational and general management roles. His passion has been the creation of innovative solutions to business, competitive and team challenges, while bridging the R&D, commercial and international worlds.
From 1985 through 2001 David held various management positions in the US and internationally with Novartis, including 8 years in the Swiss headquarters. He was responsible for launching several new products globally and in local markets. From 2002-2003, David was CEO of a German biotechnology company. After 17 years abroad, he returned to the US and has led several early stage companies specializing in ophthalmology, medicinal chemistry and dermatology in Southern California.
David began working with ThromboGenics in September 2010, identifying strategies for commercialization of JETREA® (ocriplasmin) in the US and EU. He led the company’s effort to secure an ex-US partner, which resulted in the selection of Alcon early in 2012. The ThromboGenics and Alcon teams received the Scrip Deal of the Year Award for 2012. As Head of Country Operations, David led the building of ThromboGenics’ US operations, growing the company to 95 employees and launching Jetrea in January 2013. Most recently, David has become Global Head of Corporate Development and continues to serve as President of ThromboGenics, Inc.
David holds a BA in biochemistry and French from Rice University, a PhD in molecular biophysics and biochemistry from Yale University and an MBA from the MIT Sloan School.
Stuart W. Peltz, Ph.D.
PTC Therapeutics, Inc., Chief Executive Officer
Stuart W. Peltz, Ph.D. is a co-founder of PTC and has served as Chief Executive Officer and a member of the board of directors since the company’s inception in 1998. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz has published over 80 publications in the area of post-transcriptional control processes and has received a number of scientific awards, including being elected as a Fellow of the American Academy for the Advancement of Science. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin. He was the 2014 recipient of the BioNJ Dr. Sol J. Barer Award for Vision, Innovation and Leadership.
Cyclacel Pharmaceuticals, Inc., President & Chief Executive Officer
Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has 30 years of experience with biopharmaceutical companies. He was previously Vice President, International Operations and Business Development; Managing Director, Europe; and Representative Director, Japanese joint venture, at The Liposome Company, subsequently acquired by Elan. He held various executive roles at Bristol-Myers Squibb Company, most recently as Vice President, Pharmaceuticals Central and Eastern Europe. He was Head of European Marketing and Sales, Head of Corporate Development and one of the first employees of Centocor, subsequently acquired by Johnson & Johnson, and worked in Business Development at Novartis AG.
He holds a BA from Williams College and an MBA and Master’s degree in Hospital Management with honors, from the Kellogg Graduate School of Management, where he serves on the Kellogg Biotech Advisory Board. He also serves on the Board of Trustees of BioNJ.
Alan L. Rubino
Emisphere Technologies, Inc., Chief Executive Officer
Alan L. Rubino joined Emisphere in 2012 as President and Chief Executive Officer. Upon joining, he was also appointed as Class II Director of the Company. Mr. Rubino’s career spans over 30 years at every level of the biopharmaceutical industry.
Previously, he was President and CEO of New American Therapeutics Inc., a private specialty pharmaceutical company that acquired, marketed and developed therapeutic products and achieved major success through the acquisition, marketing, and eventual sale of its herpes labialis drug, Denavir® where the team tripled sales in 18 months and sold the asset for a multiple of three times sales. Mr. Rubino served before New American Therapeutics, Inc. as the CEO and President of Akrimax Pharmaceuticals, where he and team acquired Tirosint® and NitroMist®, two key NDA approved launch products. Rounding out his background, he had also been President and COO of another publicly-held entity, Pharmos Corporation, where he led the transformation of the company through the acquisition of Vela Pharmaceuticals. Mr. Rubino also spent four years in senior leadership positions on the strategic services side of the healthcare sector with two other public companies, Cardinal Health and PDI Inc.
A major portion of Mr. Rubino’s highly successful career includes his 24 years at Hoffmann-La Roche, now Genentech (a subsidiary of Roche) which remains one of the world’s top 10 biopharmaceutical companies. At Roche, he was a corporate officer and member of the U.S. Executive Committee. He held a variety of key senior executive positions that encompassed business operations, business strategy, human resources, marketing, sales, corporate development and strategic planning.
Mr. Rubino currently serves on the Corporate Boards of Aastrom Biosciences, Genisphere, Inc. and Sanuwave Health, Inc. For the past 17 years, he has served on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. Mr. Rubino holds a B.A. in economics from Rutgers University along with a full minor in biology and chemistry.
Janssen Biotech, Inc., Janssen Pharmaceutical Companies of Johnson & Johnson, President, Oncology
Scott began his career with Johnson & Johnson 24 years ago in R&D developing high-throughput screening assays for Drug Discovery followed by several years in Clinical Research and Development. He has enjoyed a broad and diverse career holding various discovery, clinical development, sales, marketing, and managed markets positions across the Johnson & Johnson family of companies.
In his current position, Scott is responsible for leading Janssen’s Oncology business unit which is responsible for the commercialization of Janssen’s oncology portfolio in the United States.
Most recently, Scott served as the Vice President for Johnson & Johnson Health Care System’s Strategic Customer Group and served on the Janssen North America Pharmaceuticals Leadership Team as the market access leader. He also served, and continues to serve, as a Governance Committee member for the Experienced Commercial Leadership Development Program.
Previously, Scott served as Vice President of Immunology Marketing responsible for Janssen Biotech’s Immunology portfolio of Remicade, Stelara, and Simponi. He also led the Janssen Marketing Leadership Committee addressing marketing interests and needs across various Janssen business units.
Scott also currently serves on the National Pharmaceutical Council board of directors as J&J’s representative.
Scott holds a BA degree from Rutgers, The State University of New Jersey where he double-majored in molecular biology and philosophy. He also received his MBA from University of Phoenix.